DESTINY: An open-label, multinational, multicenter, phase 3b/4 study of trastuzumab deruxtecan in patients with or without baseline brain metastasis with previously treated advanced/metastatic her2-positive breast cancer (DESTINY-Breast12)

Principal investigator: Johanna Mattson
Trial site: HUS Comprehensive Cancer Center